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Abstract
Background: Molecular resistance detection (MRD) of resistance to second-line anti-tuberculous drugs provides
faster results than phenotypic tests, may shorten treatment and allow earlier separation among patients with and
without second-line drug resistance.
Methods: In a decision-analytical model we simulated a cohort of patients diagnosed with TB in a setting where drug
resistant TB is highly prevalent and requires initial hospitalization, to explore the potential benefits of a high-throughput
MRD-assay for reducing potential nosocomial transmission of highly resistant strains, and total costs for diagnosis of drug
resistance, treatment and hospitalization. In the base case scenario first-line drug resistance was diagnosed
with WHO-endorsed molecular tests, and second-line drug resistance with culture and phenotypic methods.
Three alternative scenarios were explored, each deploying high-throughput MRD allowing either detection of
second-line mutations in cultured isolates, directly on sputum, or MRD with optimized markers.
Results: Compared to a base case scenario, deployment of high-throughput MRD reduced total costs by 17-21 %. The
period during which nosocomial transmission may take place increased by 15 % compared to the base case if MRD
had currently reported suboptimal sensitivity and required cultured isolates; increased by 7 % if direct sputum analysis
were possible including in patients with smear-negative TB, and reduced by 24 % if the assay had improved markers,
but was still performed on cultured isolates. Improved clinical sensitivity of the assay (additional markers) by more than
35 % would be needed to avoid compromising infection control.
Conclusions: Further development of rapid second-line resistance testing should prioritize investment in optimizing
markers above investments in a platform for direct analysis of sputum.
Background
Tuberculosis (TB) remains a major health problem.
Multidrug-resistant tuberculosis (MDR-TB) is present in
3.6 % of new and 20 % of previously treated TB cases
globally, and in over 20 and 50 % of TB patients respect-
ively in some of the Eastern European and former Soviet
Union countries [1]. MDR-TB is defined by resistance to
at least isoniazid (INH) and rifampicin, the most power-
ful first-line anti-TB drugs [2]. Patients with additional
resistance to second-line drugs constitute 32 % of MDR-
patients globally [1]. These include patients with exten-
sively drug resistant (XDR) TB, i.e. resistance to any
fluoroquinolone (FQ) and to at least one of three sec-
ond-line injectable drugs (SLID) capreomycin, kanamycin
and amikacin [2] in addition to multidrug-resistance, or
with resistance to one of these drug-classes (pre-
XDR-TB). Phenotypic testing methods to determine
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drug susceptibility (DST) are reproducible and pre-
sumed to correlate with clinical response for most
drugs, but take at least 3–5 weeks after initial culture
and require a biosafety level-3 laboratory [3, 4]. In
settings where additional resistance to second-line
drugs is common, the influence of phenotypic DST
on the selection of the proper initial treatment and
containment of the spread of MDR-TB and (pre-
)XDR-TB is therefore limited.
Molecular assays provide much more rapid results
than phenotypic DST [3–5] and if results are corre-
lated with clinical response have a number of poten-
tial benefits. Rapid knowledge of resistance mutations
for first- and second-line drugs prior to initiation of
anti-TB therapy would increase the probability that
an effective treatment regimen is selected at treat-
ment onset rather than a (gradual) adjustment from
an empirical presumptive regimen to an individualized
regimen due to the delayed knowledge of drug resist-
ance [6]. It would also shorten the time that patients
with additional resistance to second-line drugs remain
infectious due to inadequate empirical treatment. Es-
pecially in countries where MDR patients are hospi-
talized during the first several weeks to months of
treatment until sputum cultures are negative [1], earl-
ier resistance results for second-line drugs would allow
better infection control. Earlier separation of MDR-TB
from pre-XDR and XDR-TB patients could help control
nosocomial transmission of highly resistant strains [7].
Further, earlier initiation of individualized treatment could
potentially reduce costs for drugs and patient care if it
shortens the duration of the overall treatment period.
In the context of the development of a high-throughput
multiplex assay for molecular resistance detection (MRD),
we used a decision analysis to explore the potential bene-
fits of obtaining second-line drug resistance information
faster by a high-throughput MRD-assay that requires
cultured isolates [8]. The example for our model is
the Multiplex Ligation-dependent Probe Amplification
(MLPA) technology which relies on amplification of
sequence-specific probes rather than amplification of gen-
etic targets and allows multiplexing of up to 50 genetic
markers in the Mycobacterium tuberculosis genome [8].
A pilot demonstrated operational feasibility of a prototype
of this high-throughput technology in a regional labora-
tory in a high MDR-TB setting. The clinical accuracy of
the prototype assay in detecting molecular resistance to
first and second-line drugs is under evaluation, and is in-
fluenced by the composition of genetic markers targeted
[8]. We explored the potential of this high-throughput
MRD technology for reducing nosocomial transmission of
(pre-)XDR-TB after TB diagnosis and cost for treatment,
hospitalization and diagnosis of drug resistance, assuming
clinical accuracy as published for another MRD technology
[9]. In addition, we explored how much these outcomes
could be improved by allowing direct testing of sputum
(optimized analytical sensitivity [10]) versus optimization
of molecular targets to improve clinical accuracy [10].
Methods
We modeled a cohort of patients who were diagnosed
with TB and simulated four scenarios, representing
different diagnostic algorithms for diagnosing drug-
resistant TB and different levels of optimization of the
high-throughput multiplex assay for MRD (Fig. 1, Table 1).
The analysis took a TB program perspective and consid-
ered costs and effects that occurred while patients were
taken in care of by the TB program from the moment of
TB diagnosis (since that is the time that can be altered by
the test of interest). The primary outcomes were total
costs for diagnosis and treatment and potential nosoco-
mial transmission person months (PNTPM), which were
infectious person-months (IPM) during which a patient
could nosocomially transmit a pre-XDR or XDR Mycobac-
terium tuberculosis (MTB) strain to other TB patients
during joint hospitalization. This included potential trans-
mission of (pre-)XDR-TB to patients with MDR-TB and
pre-XDR-TB to patients with pre-XDR-TB but not the
same resistance pattern (i.e. either SLID or FQ). PNTPM
ended when the correct drug-resistance pattern was iden-
tified and correct infection control measures could be
taken. Additional outcomes were the total IPM from the
moment of TB diagnosis until sputum culture conver-
sion, number of patients requiring future retreatment,
and death.
An overview of the model structure and assumptions
is provided below. A full list of model parameters is
shown in Tables 2 and 3. Detailed assumptions and out-
come definitions are in the Additional file 1.
Population
The setting had the epidemiological characteristics of
the Republic of Georgia, which is a high-MDR setting
with an estimated TB incidence of 116 per 100,000 in
2012, of whom approximately ¾ were patients with pul-
monary TB (PTB) [1]. We assumed patients were diag-
nosed with PTB either by sputum smear microscopy, the
Xpert MTB/RIF assay (Cepheid, Inc. (Sunnyvale, CA)
[Xpert]), or clinically (but presumably detectable by Xpert).
TB diagnosis is decentralized, but DST is centralized in
one laboratory serving a population of 4.3 million [11].
The cohort combined new and previously treated pa-
tients, was divided into sputum smear-positive and
smear-negative patients, and into six different drug
resistance patterns: pan-susceptible, INH monoresistant,
MDR, MDR plus fluoroquinolone-resistant (pre-XDR-F),
MDR plus injectable-resistant (pre-XDR-I) and XDR
(Table 2). The distribution of drug resistance reflected that
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of the Georgian TB patient population [7, 11, 12], and
took into account a prevalence of 9.2 % (7.9–11 %) MDR-
TB among new patients and 31 % (27-35 %) in previously
treated patients [11]. HIV-status was not considered.
Diagnostic scenarios
The four diagnostic scenarios that we compared (Table 1)
comprise a base case, and three scenarios included a
high-throughput multiplex assay for molecular resist-
ance detection (hereafter ‘high-throughput MRD-assay’)
was employed. Treatment was initiated as described in
the ‘Treatment’ paragraph.
Base case
The base case was a simplification of the use of alterna-
tive tests as currently done in Georgia. The line probe
assay for first-line drug mutations ([LiPA1] GenoType
MTBDRplus (Hain Lifescience GmbH, Nehren, Germany)
and Xpert were used in smear-positive and smear-negative
patients respectively to detect resistance against first-line
drugs. If rifampicin resistance was found, culture on liquid
and solid media was initiated and phenotypic DST was
used to confirm drug susceptibility, for first-line drugs in
automated mycobacterium liquid growth identification
tubes ([MGIT] BACTEC MGIT 960, Becton Dickinson
[BD] Biosciences, Sparks, MD) and for second-line drugs
on Löwenstein–Jensen medium (LJ).
A. Rapid test following culture
This scenario employed a high-throughput
MRD-assay that can be used on cultured isolates
but not directly on clinical specimens (e.g. sputum).
The clinical sensitivity and specificity [10] of the
assay for each drug were as shown in Table 1.
MTB isolates obtained from MGIT culture were
tested with the high-throughput MRD-assay to
detect resistance mutations for second-line drugs,
thus replacing phenotypic DST for second-line
drugs in the base case. Since obtaining isolates
takes time [4], first-line drug resistance testing
was performed with the same rapid standard
of care tests (LiPA1 or Xpert) as applied in the
base case.
B. Improved analytical sensitivity
This scenario employed the assay of scenario A,
but hypothesized to have optimized analytical
sensitivity so that it could be applied directly on
clinical specimens (sputum) of both smear-positive
Fig. 1 Schematic presentation of the modeled scenarios. Legend/footnote: Scenarios: a. = Rapid test following culture; b. Improved analytical
sensitivity; c. Improved clinical accuracy; TB = pulmonary tuberculosis; DR = drug resistance; Sm + =sputum smear positive; Sm- = sputum smear
negative; LiPA1 = Line Probe Assay for first-line drugs; Xpert = Xpert MTB/RIF assay; MRD =Molecular resistance detection; MGIT = Mycobacterial
Growth Inhibitor Tube; LJ = Löwenstein-Jensen; DST = Drug Susceptibility Testing; SUS = susceptible TB; INH mono = isoniazide mono resistance;
RR = rifampicin resistance; MDR = multi-drug resistance, defined as resistance to rifampicin and isoniazid; XDR = extensively drug-resistant
tuberculosis; PDR = poly drug resistance (to first-line drugs but not rifampicin)
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Table 1 Overview of the four diagnostic scenarios to diagnose drug-resistant tuberculosis that are compared in the model
Base case Deployment of high-throughput MRD assay
Scenario A. MRD assay following culture B. Improved analytical
sensitivity
C. Improved clinical accuracy
Resistance test for first-line drugs
Assay Smear+ LiPA1 LiPA1 rapid MRD LiPA1
Smear- Xpert Xpert rapid MRD Xpert
Specimen directly on sputum directly on sputum directly on sputum directly on sputum
Accuracy: sensitivity;
specificity
rifampicin 99.0; 99.0 % as Base case as Base case 99.8; 99.8 %
isoniazid 96.0; 100 % [28] 99.2; 100 %
(Optimizeda)
Resistance test for second-line drugs
Assay DST on LJ rapid MRD rapid MRD rapid MRD
Specimen cultured isolate cultured isolate directly on sputum cultured isolate
Accuracy: sensitivity;
specificity
fluoroquinolones 100 % (definition) 83.1; 97.7 % as A 96.6; 99.5 %
second-line
injectable drugs
79.5; 95.8 % [9] 95.9; 99.2 %
(Optimizeda)
Treatment regimen individualization
First-line regimen Standard regimen Standard regimen Standard regimen Standard regimen
Second-line
regimen
Empirical at treatment initiation,
individualized after DST result (2+ months)
Empirical at treatment initiation,




Empirical at treatment initiation, individualized
after culture + MRD result (2+ weeks)
Main assumptions: The sensitivity and specificity of molecular tests to detect Rifampicin and INH resistance are the same for all molecular tests (LiPA, MLPA, Xpert MTB/RIF) and are taken as the values of LiPA [29]
MRD Molecular Resistance Detection, DR drug resistance, LiPA1 Line Probe Assay for first-line TB drugs, Xpert Xpert MTB/RIF assay
2+ =2 or more
















Table 2 Model parameters for cohort proportions, diagnostic test performance and costs
PE Range Source, scenario
Cohort proportions
Proportion of PTB patients who are sputum-smear positive 0.64 0.62 0.65 [29] α
Susceptible to all first line drugs, or resistance to either streptomycin,
ethambutol or pyrazinamide, or combinations of those.
0.71 0.75 0.55 [29] α
IHN mono resistance, which may or may not include resistance to other
first line drugs streptomycin, ethambutol, and/or pyrazinamide (poly resistance),
but not rifampicin
0.127 0.128 0.122 [29] α
Footnote (a)
Rifampicin resistance with- or without INH resistance, without additional resistance
to 2nd line drugs. Resistance to ethambutol and/or pyrazinamide may or may
not be present.
0.108 0.073 0.212 [29] α
MDR with additional resistance to ≥1 fluoroquinolone(s) but not to second-line
injectable drugs (pré-XDR)
0.008 0.006 0.015 [29] α
MDR with additional resistance to ≥1 SLID but not fluoroquinolones (pré-XDR) 0.044 0.032 0.087 [29] α
XDR: MDR with additional resistance to ≥1 fluoroquinolones and ≥1 SLID. 0.008 0.007 0.014 [29] α
Diagnostic accuracy parameters
Sensitivity of molecular tests in detecting rifampicin resistance
(assumed to be the same as LiPA)
0.99 0.96 1.00 [28] α
Sensitivity of molecular tests in detecting INH resistance
(assumed to be the same as LiPA)
0.96 0.93 1.00 [28] α
Sensitivity of molecular tests in detecting resistance to fluoroquinolones 0.831 0.787 0.867 [9] δ
Sensitivity of molecular tests in detecting resistance to SLID, taken as the sensitivity
of LiPA sl to detect capreomycin resistance
0.795 0.583 0.914 [9] δ
Specificity of molecular tests in detecting rifampicin resistance
(assumed to be the same as LiPA)
0.99 0.98 1.00 [28] α
Specificity of molecular tests in detecting INH resistance (assumed to be the same as
LiPA)
1.00 0.99 1.00 [28] α
Specificity of molecular tests in detecting resistance to fluoroquinolones 0.977 0.943 0.991 [9] δ
Specificity of molecular tests in detecting resistance to SLID, taken as the
sensitivity of LiPA sl to detect capreomycin resistance
0.958 0.934 0.973 [9] δ
Sensitivity and specificity of DST for resistance to 1st and 2nd line drugs 1 - model assumption β
Repeat testing (Proportion of tests with invalid results requiring repeat testing, for:)
Xpert MTB/RIF 0.011 0.0004 0.020 [30] γ
LiPA 0.027 0.007 0.068 [3] γ
mycobacterial culture 0.052 0.048 0.057 [31] γ
high-throughput MRD-assay 0.027 same as LiPA; δ model
assumption
phenotypic DST 0 model assumption; β footnote (b)
Median number of days to resulta days sd source
MTBDRplus assay (LiPA) 3.0 1.7 [4]; γ footnote (c)
LJ culture 34.1 11.3 [4] β
MGIT culture 8.9 3.9 [4] γ
LJ DST 67.5 15.0 [4] β
MGIT DST 21.6 9.3 [4] β
high-throughput MRD assay in scenarios A and C 6.0 3.0 Model assumption; footnote (d)
high-throughput MRD assay in scenario B 3.0 1.5 Model assumption; footnote (e)
Xpert MTB/RIF 0 Model assumption; γ footnote (f)
Median days from lab result until clinical review and treatment initiation
for a standard treatment regimen (1st line or empirical 2nd line) 1 [32] α
for an individualized regimen (assuming additional consultation) 4 Model assumption α
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and smear-negative Xpert-positive patients, and
thereby replaced all other tests for DR detection of
first- and second-line drugs. The accuracy of the
high-throughput MRD-assay in identifying clinical
resistance against first-line and second-line drugs
was the same as in scenario A.
C. Improved clinical accuracy
This scenario employed the assay of scenario A, but
hypothesized to have optimized accuracy in
identifying clinical resistance, e.g. by adding
additional molecular markers. Since 100 % sensitivity
and specificity may be unattainable we simulated
that the sensitivity and specificity would improve by
80 % towards the target of 100 %, implying that for
each drug in the model the proportions false-
negatives and false-positives reduced by 80 % (see
Additional file 1). Analytical sensitivity was the same
as in scenario B, so cultured isolates were required
and LiPA1 and Xpert were used for first-line resist-
ance testing.
We assumed that the sensitivity and specificity of mo-
lecular tests for detecting rifampicin and isoniazid resist-
ance were the same for all molecular tests LiPA1, Xpert,
Table 2 Model parameters for cohort proportions, diagnostic test performance and costs (Continued)
Median days from treatment initiation to sputum culture conversion
in patients with susceptible TB or INHmono resistance (days, sd) 34 26 [33–35] α
in patients with MDR-TB on an appropriate regimen, (days, 95 % CI) 61 59 67 [13] α
in patients with XDR-TB in high-throughput RMD scenario (days, 95 % CI) 75 60 90 [14] δ
Increase in duration of préXDR (SLID res) in baseline 0.55 [15] β
Increase in duration of préXDR (FQ res) in baseline 0.72 [15] β
Time to failure
Months to failure on a first-line regimen 5 (15;30) α
Months to failure on a second-line regimen 4 (15;30) α
Infectious time in XDR patients who fail 24 Model assumption
(duration of treatment) α
Per-test unit cost for diagnostic tests US$ 2013 (min, max)
Sputum smear [2] 3.34 2.42 5.08 [17] α
Xpert PEPFAR pricing 17.29 15.66 18.92 [18] γ
high-throughput MRD-assay - ratio compared to per-test unit costs of LiPA 2 0.5 4 model assumption δ
DST 1st line (MGIT) 44.56 40.05 49.07 [18] β
DST 2nd line (LJ) 25.35 20.68 30.02 [18] β
Line Probe Assay (LiPA) 21.32 18.45 24.18 [18] γ
LJ culture 18.48 11.08 33.30 [17] γ
MGIT culture 18.48 11.08 33.30 [17] γ
Treatment cost parameters US$ 2013 (min, max)
First-line treatment courseb 945 629 1419 [19] α
Second-line treatment course for MDR 4176 2341 7449 [19] α
Ratio of pré-XDR regimen cost compared to MDR regimen cost 2 [20] α
Ratio of XDR regimen cost compared to MDR regimen cost 3 [20] α
Hospitalization for MDR/XDR, cost per dayb 67 [1] α
The modeled scenarios are: Base Case; MRD-A. Rapid MRD assay following culture; MRD-B. Improved analytical sensitivity; MRD-C. Improved clinical accuracy. The
Greek symbol in the first column indicates to which scenarios the parameter apply: α to all four scenarios; β to the Base Case only; γ to the Base Case, MRD-A and
-C but not to MRD–B; δ to the MRD scenarios (A, B, C) but not the Base Case
(a): low end of the range reflects the distribution among new patients and high end the distribution among previously treated patients.(b): if an isolate is
obtained on culture, we assume DST will always give a valid result. (c): adjusted (was 4.2 days in the publication in a special study performing assays 2–3 times a
run per week on 2–8 samples per run. We adjusted for current practice where LiPAs are run daily (50–60 samples per week). (d) assumes a batch of ± 50 once a
week. (e): assumes a patient volume that requires batch testing of ± 50 every 1–2 (working) days. (f): Time counts from TB diagnosis and Rifampicin result comes
at the same time as the TB diagnostic result
Abbreviations; PE point estimate, PTB pulmonary tuberculosis, MDR multi-drug resistance, defined as resistance to rifampicin and isoniazid [2], SLID second-line
injectable drugs, XDR extensively drug-resistant, INH isoniazide, LiPA line probe assay, LJ Löwenstein-Jensen, MGIT Mycobacterial Growth Inhibitor Tube, DST Drug
Susceptibility Testing, sd standard deviation, CI confidence interval
aExcluding requirement for repeat testing
bFirst-line treatment applies to catI and catII treatment; hospitalization costs are estimated from studies in the same region [21] and average number of hospital
days in 2012 [36]
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Table 3 Results of the primary analysis for a simulated cohort of 1000 patients diagnosed with TB


















(US$ 2013); % change
c.t. base case
Diagnostic costs
(US$ 2013); % of
total costs




Base case 1000 59 1,710 66 4 % $3,557,923 0 % $44,617 1.2 % 39.1 125
High-throughput MRD-assay:
A. following culture 1000 59 45 76 % 1,603 −6 % 76 +15 % 5 % $2,960,243 −17 % $39,837 1.3 % 40.1 (+2.5 %) 127 (+1.6 %)
B. Improved
analytical sensitivity
1000 59 45 76 % 1,617 −5 % 71 +8 % 4 % $2,821,923 −21 % $48,816 1.7 % 40.1 (+2.5 %) 129 (+3.9 %)
C. Improved clinical
accuracy
1000 59 57 96 % 1,604 −6 % 50 −24 % 3 % $2,937,299 −17 % $39,233 1.3 % 40.1 (+2.5 %) 124 (−0.4 %)
IPM infectious person-months, c.t. compared to, PNTPM potential nosocomial transmission person-months; i.e. IPM in (pre-)XDR patients that may cause nosocomial transmission, MRD molecular resistance detection
aTotal costs combine diagnostic, treatment, hospitalization costs
















and high-throughput MRD (except in the optimized
clinical accuracy scenario B) and were taken as the pub-
lished values of LiPA1 [5]. The sensitivity determined
the number of drug-resistant cases that are correctly
identified by the test, and specificity the number of pa-
tients treated for resistance due to a false positive test
result. This implied that all molecular methods in the
base case, and high-throughput MRD scenarios A and C
detect and miss the same cases compared to phenotypic
DST. The accuracy of the high-throughput MRD-assay
in detecting mutations conferring resistance to second-
line drugs equaled that of second-line LiPA [10], as these
values are currently achievable with a molecular test.
Phenotypic DST was taken as the reference standard,
implying a sensitivity and specificity equal to 100 % for
all resistance patterns. Additional details on diagnostic
assumptions are provided as Additional file 1.
Treatment assumptions
Treatment initiation was according to test results, re-
gardless of a prior history of TB treatment: A standard
6 month first-line regimen if results showed susceptible-
TB, 9 months if in the INH-mono-resistance category
[6]. In the base case and in high-throughput MRD sce-
narios A and C an empirical standardized second-line
regimen was initiated if rifampicin resistant [6]. The
empirical second-line regimen was adjusted to an indi-
vidualized regimen, if needed, once the full resistance
profile was known. In scenario B (optimized analytical
sensitivity) second-line treatment was individualized
from the onset.
The probabilities of treatment outcomes (cure/comple-
tion, failure, default or death) depended on the treatment
regimen and its adequacy for the drug susceptibility
pattern (Additional file 1). In case of treatment fail-
ure, patients were retested according to the scenario
and switched to an alternative regimen if an under-
lying resistance pattern had been misdiagnosed earlier
on, as further described in the Additional file 1.
We modeled resistance to the most important drugs
in second-line treatment each as one group implying
that if resistance to one drug in the category is present,
none of the drugs in the category were assumed to be
effective.
Costs
Costs were divided into diagnostic costs for TB bac-
teriological tests, and treatment costs which included
hospitalization, and drugs and additional costs like
treatment monitoring. All costs were taken from the
literature (Table 2) and converted to US$ 2013 [22].
In the primary analysis we assumed the per-test unit-cost
of the high-throughput MRD-assay to be twice that of
LiPA1 and explored a wider range in a sensitivity analysis.
Hospitalization costs assumed that MDR/(pre-)XDR
patients were hospitalized during their IPMs. Patients
on first-line regimens did not accrue hospitalization costs,
since these costs were small compared to MDR/(pre-)XDR
and the same in all scenarios [1].
Analysis
We reported all model outcomes assuming a cohort simu-
lation of 1000 patients diagnosed with TB. In the primary
analysis the point estimates (PE) of all parameter values
(Table 2) were used. We conducted deterministic sensitiv-
ity analyses to explore the effect of uncertainty in the
values of key parameters and the effect of assumptions on
the primary outcomes (total costs and PNTPM) and on
diagnostic costs per (pre-)XDR patient identified, as out-
lined in the Additional file 1.
Ethical approval




Infectious period of time
Following the distribution of drug-resistance patterns,
our simulated cohort of 1000 patients diagnosed with
TB had 59 patients with (pre-)XDR, detectable by
phenotypic DST. In MRD scenarios A and B, 45 (76 %)
were correctly identified at an earlier point in time com-
pared to the base case, and 57 (96 %) in scenario C
(Table 3). The remaining patients were identified after
treatment failure. The number of IPM in (pre-)XDR pa-
tients that may lead to nosocomial transmission was 66
in the base case, and reduced by 24 % in scenario C, but
increases by 15 % and 7 % in scenarios A and B, respect-
ively, due to FQ and/or SLID resistance patterns having
been missed in some of the patients. The total number
of IPM in in the cohort was 1710 in the base case, and
reduced by 5–6 % in all three MRD scenarios.
Cost
The total costs to test for drug resistance and treating all
1000 TB patients in the base case were $3,557,923 of
which costs for diagnostic tests comprised 1.3 %. Total
costs in the MRD scenarios reduced by between 17–21 %,
almost entirely due to a reduction in cost for treatment
and hospitalization. Diagnostic costs were highest in sce-
nario B where the costs for the molecular assay applied to
all patients, but remained a small fraction of the combined
diagnostic, treatment and hospitalization costs. The pro-
jected number of deaths and retreatment cases in scenario
C remained the same as in the base case, and increased by
2.5 % in the MRD scenarios due to patients starting on an
inappropriate treatment regimen.
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Deterministic sensitivity analysis
The largest variation (Fig. 2; Additional file 2: Table S1) in
total costs was caused by variation in the prevalence of MDR
and (pre-)XDR in the cohort (Fig. 2 - Panel I), followed by
variation in treatment and hospitalization costs. The ranking
of the scenarios in terms of total costs did not change in any
sensitivity analysis. Diagnostic costs per (pre-)XDR patient
identified (Panel III) were most sensitive to assumptions
about the per-test costs of the high-throughput MRD-assay,
especially for scenario B. If this cost increased or decreased
by 200 %, the diagnostic costs per (pre-)XDR patient in sce-
nario B changed accordingly and became lowest or highest
of all scenarios. The effect on total costs remained however
between −1 to +2 %, negligible compared to effects of vari-
ation in treatment and hospitalization costs. If treatment and
hospitalization costs increased or decreased by 50 %, total
costs in all scenarios increased or decreased by 16–22 %.
The number of PNTPM (Fig. 2 - Panel II) was, as ex-
pected, also most sensitive to variation in the prevalence
of MDR and (pre-)XDR in the cohort, followed by the
sensitivity of the assays for detecting FQ and SLID re-
sistance. In scenario C (optimized markers) the number
of PNTPM would fall below the base case level if the
proportion of false-negatives and false-positives reduced
by at least 35 % (Fig. 3). If assay sensitivity was set at
100 % (equal to phenotypic DST), rapid DR testing re-
duced nosocomial transmission time by more than half.
If we assumed that the time to obtain a cultured iso-
late for high-throughput analysis increased to the days
required for LJ culture, PNTPM increased by 30 % com-
pared to the use of MGIT in scenarios A and C, which
first required culture. The effect of variation in assump-
tions about the time to sputum conversion in (pre-)XDR,
about error rates of diagnostic procedures (contaminated
cultures etc.), and of increased turnaround time by 2 weeks
(e.g. due to transportation of specimens) was small and
changed the number of PNTPM on the order of 2–8 %
compared to the primary analysis. If we assumed that con-
firmatory phenotypic DST (first- and second-line) would
be done in addition to rapid MDR in scenarios A, B and C
to avoid increase in retreatment and death, diagnostic cost
increased by 33–42 % and comprised 1.8–2.4 % of total
cohort costs which increased by 0.4–2 %.
Discussion
We conclude from our model that introducing a high-
throughput MRD-assay as the primary diagnostic test
for faster detection of resistance-conferring mutations
Fig. 2 One-way sensitivity analysis showing the magnitude of the effect of each listed parameter or assumption on Total costs, Nosocomial
transmission months and Diagnostic cost per (pre-)XDR case detected. Legend: MRD =molecular resistance detection, FLQ = fluoroquinolones,
SLID = injectable aminoglycosides, MDR =multi-drug resistance, defined as resistance to rifampicin and isoniazid, XDR = extensively drug-resistant.
* indicates a change in ranking
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for second-line anti-tuberculosis drugs could potentially
reduce the combined costs for diagnosis, treatment and
hospitalization of TB patients by 17–21 %. Due to the
low clinical sensitivity, the use of molecular assays for
second-line drug resistance may however have perverse
consequences in terms of nosocomial transmission in
settings where MDR and (pre-)XDR patients are hospi-
talized until sputum culture conversion has been con-
firmed. A longer hospitalization period of missed cases
of (pre-)XDR patients may increase opportunities for
nosocomial transmission to patients infected by MDR-
TB that is susceptible to second-line drugs.
In terms of improving the performance of high-
throughput MRD-assays, our results suggest that greater
impact on reducing infectious time in general and
potential for nosocomial transmission is expected from
increasing clinical sensitivity and specificity (optimized
markers) than from optimizing analytic sensitivity (allow-
ing direct analysis of sputum) without improvement of the
markers. This still applies if the turnaround time of an im-
proved assay requires MGIT culture and 1–2 weeks to
send specimens and return results to peripheral facilities.
We found that costs for diagnostic tests remain a small
proportion of total costs for diagnosis and treatment com-
bined, even if the average per-test costs of MRD doubled
compared to our primary assumption.
The rapid second-line assay that we modelled com-
bines high-throughput features of the MLPA [8] with
published accuracy of second-line LiPAs [10]. A pilot
has demonstrated operational feasibility of the MLPA
Fig. 3 The effect of variation in improvement in the clinical sensitivity and specificity of the assay molecular markers in scenario C (improved
markers) on potential nosocomial transmission person months. Legend: The horizontal axis reflects the proportional decrease in false-negative
(FN) and false-positive (FP) results (reflecting improvement in clinical accuracy) for second-line resistance in scenario MRD C. The vertical axis
represents the number of potential nosocomial transmission person months (PNTPM) per 1000 TB patients in the simulated cohort. Scenario MRD
A. represents the MRD assay following culture; MRD B. Improved analytical sensitivity; In scenarios MRD A. and B. the sensitivity and specificity are
as reported in the primary analysis. In scenario MRD C. (improved clinical accuracy) the default proportion reduction in FN and FP results was 0.8
in the primary analysis. The vertical dotted line represents the minimum decrease in the proportion FN and FP that is required to ensure that
PNTPM in scenario MRD C are at least equal to the Base case. The PNTPM in scenarios MDR A and B exceed that of the Base case, reflecting
greater potential for nosocomial transmission
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technology in a centralized reference laboratory in a high
MDR-TB setting to analyze batches of cultured isolates
(Sengstake et al. manuscript in preparation). The clinical
accuracy of the prototype assay in detecting molecular
resistance to first and second-line drugs is under evalu-
ation, and is influenced by the composition of genetic
markers targeted. For further development of the high-
throughput bead-based MLPA technology [8] that served
as the example for this study, our results suggest that fur-
ther investments should first be in improving markers to
reach a sensitivity beyond the values that we used in this
modeling study. A possible increase in per-test unit costs
of an improved assay would be outweighed by reductions
in treatment costs. Investment towards an improved high-
throughput assay for centralized use may be preferred
above investment in improved rapid assays that allow
decentralized detection of second-line mutations directly
from sputum, as such a test would require excellent ana-
lytic sensitivity in smear-positive as well as smear-negative
sputum samples. As long as genetic targets are sufficiently
tailored to the local epidemic drug resistant clusters, the
MLPA technology or any other similar MRD test would
be advantageous [23]. Increasing clinical sensitivity should
not compromise specificity. In low MDR-TB settings ex-
cellent specificity would also be needed to avoid false-
positive diagnosis of M(X)DR-TB.
Our study has a number of limitations. We made sim-
plifying assumptions, such as that a multiplex molecular
assay would replace phenotypic DST for diagnosis of
second-line drug resistance. A single test would reduce
the costs and complexity of post-TB-diagnosis analysis,
including the cost related to the development of pheno-
typic DST laboratory capacity (not included in our cal-
culations), and may thereby allow the further scale-up of
second-line treatment in resource-poor settings needed
to treat a larger proportion of M/XDR-TB patients. We
acknowledge that the reality of diagnosis and treatment
of MDR-TB is complex [24]. For clinical decision mak-
ing, genotypic assays with low sensitivity may be used
alongside phenotypic DST in practice [9]. Our results
show that confirmation of second-line resistance with
phenotypic DST should remain mainstay unless the sen-
sitivity of molecular markers improves, to avoid unfavor-
able effects on infection control and patient outcomes.
In any case regular validation with phenotypic DST and
clinical response remains required, since adding more
markers will only improve sensitivity, if new strains
(carrying new drug resistance conferring mutations)
are introduced in the setting.
The assumption that if resistance to one drug in the
category is present, none of the drugs in the category
will be effective may not always be correct. Newer gener-
ation fluoroquinolones such as moxifloxacin may be ef-
fective when there is resistance to older generation
fluoroquinolones such as ofloxacins [25]. The meta-
analysis from which we sourced the MTBDRsl test charac-
teristics [10] included both studies that had DST for oflox-
acin and studies that had DST for moxifloxacin as the
reference standard, so our parameter values were a
composite for both drugs. Specificity for moxifloxacin
resistance was somewhat lower, and sensitivity some-
what higher, than for ofloxacin, so we may have over-
estimated the effects on infectious person-time, and
underestimated the effects on unnecessary treatment
changes if newer generation fluoroquinolones would
be used. Similarly, sensitivity of molecular diagnosis is
lower for kanamycin than for amikacin, and similar effects
may have occurred for the category of SLID. Nonetheless,
such variations would not affect the conclusion that a bene-
ficial effect of a MRD test requires high clinical sensitivity.
Our decision modeling approach did not take trans-
mission other than nosocomial into account and we did
not make inferences about potentially reduced transmission
due to the reduction of infectious time. Transmission de-
pends on many additional factors, including infectious time
prior to TB diagnosis and in persons who default treatment,
which are amenable to other types of interventions.
Additional benefits of second-line MRD tests were not
included in the analysis, a simplification that avoids over-
estimation of the impact of rapid second-line resistance
testing. Additional benefits include a targeted regimen
with fewer drugs compared to the empirical regimen. This
may also reduce side effects and toxicities and chances of
treatment default [26], and prevent resistance amplifica-
tion, i.e. acquired resistance against additional classes of
second-line drugs [7]. Prevention of amplification may
further reduce costs by preventing treatment failure. An-
other additional benefit may be less pre-treatment loss to
follow-up compared to phenotypic DST as a result of
much shortened time-to-result. As this study pertains to
patients who are hospitalized after TB diagnosis, effects
on pre-treatment loss to follow-up were not considered.
Our approach is novel in that we modeled IPM and the
potential of nosocomial transmission as outcomes since
those factors are direct concerns in settings with high
prevalence of MDR-TB and (pre-)XDR-TB. The purpose
of this study is to show potential trends and should not be
interpreted as a cost-effectiveness study for one particular
setting and technology. A recent modeling study sug-
gested that to be potentially cost-effective in terms of pre-
venting mortality and disability, the aggregate sensitivity
and specificity of multiplex assays for pre-XDR/XDR
should at least be 88 and 96 %, respectively [27]. Empirical
data to support model assumptions about mortality and
disability arising from inadequate treatment of pre-XDR/
XDR-TB are however scarce [27]. Although this study and
ours each compass its own uncertainty in assumptions,
both approaches point in the same direction.
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Conclusions
A high-throughput MRD-assay for early detection of re-
sistance to second-line drugs as a replacement of pheno-
typic DST could potentially reduce the combined costs for
diagnosis, treatment and hospitalization of TB patients
and may seem attractive for infection control purposes.
Low sensitivity may however compromise infection con-
trol in settings where MDR and (pre-)XDR patients are
hospitalized, and affect patient outcomes unfavorably. Fur-
ther investments to improve the overall sensitivity are
needed with a priority for improvements in clinical above
analytical sensitivity.
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